Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
Go back to Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection| Merck & Co. (NYSE: MRK) | Delayed: 148.78 +1.91 (1.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.87 | 52 Week High | $65.46 | |||
| Open | $146.79 | 52 Week Low | $47.97 | |||
| Day High | $149.19 | P/E | 101.21 | |||
| Day Low | $145.60 | EPS | $1.47 | |||
| Volume | 1,512,817 | |||||

